Lupus & antiphospholipid syndrome
Morbidity and mortality in primary versus secondary antiphospholipid syndrome: A single-center study using the 2023 ACR/EULAR criteria
Main finding · Overall mortalityResult — go to the resultAdjusted hazard ratio 5.28Authors' conclusion
SAPS is associated with higher mortality and increased CAPS risk, emphasizing the adverse prognostic impact of concomitant SLE and the need for tailored risk stratification.
Study context
- Population
- Consecutive adults evaluated for suspected APS fulfilling the 2023 ACR/EULAR APS criteria, single centre432 screened
- Participants
- 210 adults
- Exposure
- APS secondary to SLE vs primary APS
- SAPSn = 59
- PAPSn = 151reference
- Outcome
- Morbidity and mortality
Methodological detailssingle-center, observational, multivariable Cox regression
- Single-center
- Observational
- Multivariable Cox regression
Main finding
Overall mortality
Adjusted hazard ratio
5.28
By group
As reported in the abstract
Observational data: associations, not effects.
Further findings
Female sex
P < 0.001
CAPS
P = 0.01
Age at first APS-related event
P < 0.001
| Outcome | SAPS | PAPS | P value |
|---|---|---|---|
| Renal disease | 33. 9% | — withheld: not confirmed against the abstract | P < 0.001 |
— withheld: the automatic checks could not confirm the value against the abstract
Venous, arterial, recurrent thrombosis and obstetric manifestations
- Similar between groups
Factors independently associated with mortality (multivariable Cox regression)
- Increasing age at first event, aHR
- 1.1
- SAPS, aHR
- 5.28
- Renal disease, aHR
- 3.16
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →